Dated: November 22, 2002.

#### Kathryn C. Zoon,

Director, Center for Biologics Evaluation and Research.

[FR Doc. 02–30642 Filed 12–2–02; 8:45 am] BILLING CODE 4160–01–S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Health Resources and Services Administration

### Advisory Committee on Interdisciplinary, Community-Based Linkages; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act, Public Law 92–463), notice is hereby given of the following meeting. The meeting will be open to the public.

Name: Advisory Committee on Interdisciplinary, Community-Based Linkages.

Date and Time: December 8, 2002, 7 p.m.—9 p.m. December 9, 2002, 8 a.m.—5:30 p.m. December 10, 2002, 8:30 a.m.—3 p.m.

Place: Wyndham Washington Hotel, 1400 M Street, NW, Washington, DC 20005.

Agenda: Agenda items will include, but not be limited to: Welcome, plenary session on bioterrorism and public health preparedness with presentations by speakers representing the Department of Health and Human Services (DHHS), constituent groups, field experts and committee members. Meeting content will address the critical nature of bioterrorism, current activities related to public health preparedness by the DHHS, state responses to bioterrorism and public health preparedness, and how the constituency groups of the committee are incorporating and will further incorporate bioterrorism and public health preparedness into their workforce education and training efforts. Proposed agenda items are subject to change as priorities dictate.

*Public Comments:* Public comment will be permitted before lunch and at the end of the Committee meeting on December 10, 2002. Oral presentations will be limited to 5 minutes per public speaker. Persons interested in providing an oral presentation should submit a written request, with a copy of their presentation to: Jennifer Donovan, Deputy Executive Secretary, Division of State, Community and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Room 9-105, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-8044.

Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The Division of State, Community and Public Health will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file a request in advance for a presentation, but wish to make an oral statement may register to do so at the Wyndham Washington Hotel, Washington, D.C., on December 10, 2002. These persons will be allocated time as the Committee meeting agenda permits.

### FOR FURTHER INFORMATION CONTACT:

Anyone requiring information regarding the Committee should contact Jennifer Donovan, Division of State, Community and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Room 9–105, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–8044.

Dated: November 26, 2002.

#### Jon L. Nelson,

Associate Administrator for Management and Program Support.

[FR Doc. 02–30551 Filed 12–2–02; 8:45 am] BILLING CODE 4165–15–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **Substance Abuse and Mental Health Services Administration**

### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at the following websites: http://workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443–6014, Fax: (301) 443–3031

#### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840/800–877–7016, (Formerly: Bayshore Clinical Laboratory).

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264.

Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290– 1150.

Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615– 255–2400.

Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513–585–6870, (Formerly: Jewish Hospital of Cincinnati, Inc.).

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703–802–6900.

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite

- 250, Las Vegas, NV 89119–5412, 702–733–7866/800–433–2750.
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800– 445–6917.

Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800– 876–3652/417–269–3093, (Formerly: Cox Medical Centers).

Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 239–561–8200/800–735–5416.

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31602, 912–244–4468.

DrugProof, Divison of Dynacare, 543 South Hull St., Montgomery, AL 36103, 888–777–9497/334–241–0522, (Formerly: Alabama Reference Laboratories, Inc.).

DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2661/800–898–0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119Mearns Rd., Warminster, PA 18974, 215–674–9310.

Dynacare Kasper Medical Laboratories\*, 10150–102 Street, Suite 200, Edmonton, Alberta, Canada TJ5 5E2, 780–451–3702/800–661–9876.

ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662–236– 2609.

Express Analytical Labs, 3405 7th Avenue, Suite 106, Marion, IA 52302, 319–377–0500.

Gamma-Dynacare Medical Laboratories\*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ONT, Canada N6A 1P4, 519– 679–1630.

General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608– 267–6225.

Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504– 361–8989/800–433–3823, (Formerly: Laboratory Specialists, Inc.).

LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/ 800–873–8845, (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.).

Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288 / 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400 / 800–437– 4986, (Formerly: Roche Biomedical Laboratories, Inc.).

Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc., CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).

Laboratory Corporation of America Holdings, 10788 Roselle Street, San Diego, CA 92121, 800–882–7272, (Formerly: Poisonlab, Inc.).

Laboratory Corporation of America Holdings, 1120 Stateline Road West, Southaven, MS 38671, 866–827–8042/ 800–233–6339, (Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center).

Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715– 389–3734/800–331–3734.

MAXXAM Analytics Inc.\*, 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905–890–2555, (Formerly: NOVAMANN (Ontario) Inc.).

Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699, 419–383–5213.

MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651–636–7466/800–832–3244.

MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295.

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612– 725–2088.

National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350–3515.

Northwest Drug Testing, a Division of NWT Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 801–293–2300/ 800–322–3361, (Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.).

One Source Toxicology Laboratory, Inc., 1705 Center Street, Deer Park, TX 77536, 713–920–2559, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).

Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2134. Pacific Toxicology Laboratories, 6160 Variel Ave., Woodland Hills, CA 91367, 818–598–3110 / 800–328– 6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory.

Pathology Associates Medical Laboratories, 110 West Cliff Drive, Spokane, WA 99204, 509–755–8991/ 800–541–7891x8991.

PharmChem Laboratories, Inc., 4600 N. Beach, Haltom City, TX 76137, 817–605–5300, (Formerly: PharmChem Laboratories, Inc., Texas Division; Harris Medical Laboratory).

Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372/800–821–3627.

Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590/800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800– 824–6152, (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 610–631–4600/877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800–669–6995/847–885–2010, (Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories).

Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405,

\* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

\*Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (Federal Register, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 FR, 9 June 1994, Pages 29908–29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and participate in the NLCP certification maintenance program.

818–989–2520/800–877–2520, (Formerly: SmithKline Beecham Clinical Laboratories).

Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130.

S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505– 727–6300/800–999–5227.

South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176x276.

Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602– 438–8507/800–279–0027.

Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–377–0520, (Formerly: St. Lawrence Hospital & Healthcare System).

St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272– 7052.

Sure-Test Laboratories, Inc., 2900 Broad Avenue, Memphis, Tennessee 38112, 901–474–6028.

Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573–882–1273.

Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305–593–2260.

US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson Street, Fort George G. Meade, MD 20755–5235, 301–677–3714.

### Richard Kopanda,

Executive Officer, SAMHSA.
[FR Doc. 02–30385 Filed 12–2–02; 8:45 am]
BILLING CODE 4160–20–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **Substance Abuse and Mental Health Services Administration**

Correction of Application Deadline for the Grant Program, Community Collaborations to Prevent Youth Violence and Promote Youth Development (SM 03–005) (Short Title: Youth Violence Prevention Grants)

**AGENCY:** Substance Abuse and Mental Health Services Administration (SAMHSA), DHHS.

ACTION: Correction of application deadline for the grant program, Community Collaborations to Prevent Youth Violence and Promote Youth Development (SM 03–005) (Short Title: Youth Violence Prevention Grants).

SUMMARY: This notice is to inform the public that the application deadline published on November 26, 2002, for the grant program, Community Collaborations to Prevent Youth Violence and Promote Youth Development (SM 03–005) (Short Title: Youth Violence Prevention Grants), is incorrect. The correct application deadline is January 22, 2003.

#### **Program Contact**

For questions about the due date for this program or other program issues relating to this program, contact: Pat Shea, M.S.W., M.A., Special Programs Development Branch, CMHS/SAMHSA, Parklawn Building, Room 17C–26, 5600 Fishers Lane, Rockville, MD 20857. (301) 443–3655. (Email) pshea@samhsa.gov.

Dated: November 26, 2002.

#### Richard Kopanda,

Executive Officer, SAMHSA.
[FR Doc. 02–30644 Filed 12–2–02; 8:45 am]
BILLING CODE 4162–20–P

# DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4797-N-01]

Notice of Reminder for Fiscal Year 2002 HOPE VI Demolition Grant Applicants of the Need For Prior Demolition Approval

**AGENCY:** Office of the Assistant Secretary for Public and Indian Housing, HUD.

**ACTION:** Notice.

**SUMMARY:** This notice reminds potential applicants for Fiscal Year 2002 HOPE VI demolition grants, that they must secure demolition approval under section 18 of the United States Housing Act of 1937 on or before the HOPE VI demolition grant application deadline.

### FOR FURTHER INFORMATION CONTACT:

Caroline Clayton, Office of Public and Indian Housing, Room 4130, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410, telephone (202) 401–8812. (This number is not toll-free). For hearing- and speech-impaired persons, this number may be accessed via TTY (text telephone) by calling the toll-free Federal Information Relay Service at 1–800–877–8339. The section 18 demolition application form (HUD–52860) is available at http://www.hudclips.org/sub\_nonhud/html/pdfforms/52860.pdf.

**SUPPLEMENTARY INFORMATION:** HUD anticipates that it will soon publish the FY 2002 HOPE VI demolition notice of

funding availability (NOFA). This notice serves to remind public housing authorities that anticipate applying for a Fiscal Year (FY) 2002 HOPE VI demolition grant that demolition approval must be obtained on or before the HOPE VI demolition grant application deadline. Section 18 of the United States Housing Act of 1937 (42 U.S.C. 1437p) establishes the demolition approval application process for properties not already approved for demolition through a Mandatory Conversion Plan or HOPE VI Revitalization Plan. In addition, regulations at 24 CFR part 970 describe the administrative steps required to perform demolition/disposition activity in accordance with the United States Housing Act of 1937. Public housing agencies are also advised that HUD's Special Application Center, which processes demolition approval applications, requires 100 days to process an application.

This notice applies to demolition-only grants, not demolition conducted pursuant to a HOPE VI revitalization grant or a Mandatory Conversion Plan approved under applicable regulations (24 CFR part 971). Guidance on preparing a demolition approval application and links to the regulations and applicable notices, is available though HUD's Web site at <a href="http://www.hud.gov/offices/pih/centers/sac/demo\_dispo/">http://www.hud.gov/offices/pih/centers/sac/demo\_dispo/</a>. The section 18 demolition application form (HUD–52860) is available at <a href="http://www.hudclips.org/sub\_nonhud/html/pdfforms/52860.pdf">http://www.hudclips.org/sub\_nonhud/html/pdfforms/52860.pdf</a>.

Dated: November 25, 2002.

### Michael Liu,

Assistant Secretary for Public and Indian Housing.

[FR Doc. 02–30572 Filed 12–2–02; 8:45 am] **BILLING CODE 4210–33–P** 

### **DEPARTMENT OF INTERIOR**

# Bureau of Land Management [UT-060-1610-DU]

#### **Notice of Intent**

**AGENCY:** Bureau of Land Management. **ACTION:** Notice of Intent to prepare two Environmental Assessments (EAs) and consider amending the Grand Resource Area Resource Management Plan (RMP); Moab, Utah.

SUMMARY: Pursuant to the Bureau of Land Management (BLM) Planning Regulations (43 CFR 1600) this notice advises the public that the Utah Bureau of Land Management (BLM), Moab Field Office, is considering amending an